-

BostonGene Honored as Gold and Silver Stevie® Award Winner in 2024 Stevie Awards for Technology Excellence

Accolades Honor BostonGene’s AI-Powered Solutions for Accelerating Precision Oncology and Advancing Patient Care

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of artificial intelligence (AI)-driven molecular and immune profiling solutions, has received one Gold Stevie for its AI-based digital pathology platform and two Silver Stevies for its Tumor PortraitTM test and immune system profiling platform in the Stevie Awards for Technology Excellence, “the Olympics for technology.”

"We are proud to support drug developers in getting lifesaving therapies to patients faster by transforming clinical trial designs using our AI-powered technology."

Share

The Stevie Awards for Technology Excellence celebrate the remarkable accomplishments of individuals, teams, and organizations shaping the future of technology across all industry sectors.

“Receiving one Gold and two Silver Stevie Awards is an incredible recognition of our team's dedication to transforming cancer care,” said Andrew Feinberg, President and CEO of BostonGene. “We are developing and deploying pioneering AI solutions on top of our powerful discovery platform, which covers the entire molecular biology paradigm. We are truly humbled to see this leading to rapid advances in personalized medicine and improved patient outcomes. We are proud to support drug developers in getting lifesaving therapies to patients faster by transforming clinical trial designs with our AI-powered technology.”

Gold Stevie Award Winner: AI-Based Digital Pathology Platform
BostonGene's AI-based digital pathology platform received top honors for its revolutionary approach to tumor tissue analysis. The platform minimizes human error and variability by automating and standardizing the process, ensuring more accurate cancer diagnoses and biomarker identification. This breakthrough technology enables more precise, personalized treatments for cancer patients, improving outcomes and enhancing the overall standard of care.

Silver Stevie Award Winner: Immune System Profiling Platform
Additionally, BostonGene's immune system profiling platform received a Silver Stevie. This transformative solution introduces a novel classification and scoring system that correlates systemic immunity with patient responses to various cancer treatments, offering a new dimension in personalized care.

Silver Stevie Award Winner: Tumor Portrait™ test
Finally, a Silver Stevie went to BostonGene's Tumor Portrait™ test that identifies biomarkers, actionable mutations and immune microenvironment properties. Integrating DNA and RNA results into a unified report offers tailored treatment options, empowers clinicians to select the most effective therapies for their patients.

Details about the Stevie Awards for Technology Excellence and the list of 2024 Stevie winners are available at www.StevieAwards.com/Tech.

About BostonGene Corporation
BostonGene is a software-driven biotechnology company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continuously pushed the boundaries of innovation to improve patient care and accelerate drug development. Our AI-powered multiomics platform decodes cancer patients' molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets and recommend the most effective treatments. With advanced bioanalytics, an indication-specific cancer library and a next-generation CLIA-certified, CAP-accredited high-complexity laboratory, we deliver precise, clinically validated insights that propel precision medicine and advance oncology research. For more information, visit www.BostonGene.com.

About the Stevie Awards
Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Great Employers, the Stevie Awards for Women in Business, the Stevie Awards for Technology Excellence and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations and territories. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.

Contacts

Erin Keleher O'Reilly
erin.oreilly@bostongene.com
617-283-2285

Industry:

BostonGene Corporation

Release Versions
English

Contacts

Erin Keleher O'Reilly
erin.oreilly@bostongene.com
617-283-2285

Social Media Profiles
BostonGene
BostonGene - Twitter
More News From BostonGene Corporation

BostonGene Announces Collaboration with Ottimo Pharma to Optimize and Accelerate Development of First-in-Class PD-1/VEGFR2 Immuno-Oncology Therapy Using AI

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Ottimo Pharma Limited (“Ottimo”), an innovative, clinical-stage biotech company developing one-of-a-kind PD-1/VEGFR2 dual paratopic antibodies to extend the lives of patients living with cancer. The partnership will utilize BostonGene’s advanced artificial intelligence (AI) platform to apply multiomic analytics and expedite th...

BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology Development

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with AstraZeneca, a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, to advance oncology drug development using BostonGene’s multimodal AI platform. The collaboration leverages BostonGene’s foun...

BostonGene Named “Overall Immunology Company of the Year” by BioTech Breakthrough for Its AI-Driven Platform That Transforms Immuno-Oncology Drug Development Through Advanced Biomarker Discovery, Real-Time Monitoring, and Precision Patient Selection

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI foundation model for tumor and immune biology, today announced it has been named “Overall Immunology Company of the Year” in the fifth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe. BostonGene’s AI-driven platform deli...
Back to Newsroom